{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:08:37Z","timestamp":1793984917313,"version":"4.8.0"},"reference-count":220,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011821","name":"Kingdom of Saudi Arabia Ministry of Education","doi-asserted-by":"publisher","award":["ISP22-8"],"award-info":[{"award-number":["ISP22-8"]}],"id":[{"id":"10.13039\/501100011821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2024.e24559","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T07:56:02Z","timestamp":1705478162000},"page":"e24559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice"],"prefix":"10.1016","volume":"10","author":[{"given":"Hamad Ghaleb","family":"Dailah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah Abdu","family":"Hommdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi Dafer","family":"Koriri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essa Mohammed","family":"Algathlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-1278","authenticated-orcid":false,"given":"Syam","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e24559_bib1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib2","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.heliyon.2024.e24559_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/apjon.apjon_79_17","article-title":"Targeted therapy: attacking cancer with molecular and immunological targeted agents","volume":"5","author":"Wilkes","year":"2018","journal-title":"Asia Pac J Oncol Nurs"},{"key":"10.1016\/j.heliyon.2024.e24559_bib4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.soncn.2014.05.002","article-title":"Science and mechanism of action of targeted therapies in cancer treatment","volume":"30","author":"Wujcik","year":"2014","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.heliyon.2024.e24559_bib5","doi-asserted-by":"crossref","first-page":"29490","DOI":"10.1021\/acsami.9b07390","article-title":"Artemisinin-based smart nanomedicines with self-supply of ferrous ion to enhance oxidative stress for specific and efficient cancer treatment","volume":"11","author":"Luo","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.heliyon.2024.e24559_bib6","first-page":"675","volume":"vol. 39","author":"Li","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e24559_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.002","article-title":"Cancer and the immune system: the history and background of immunotherapy","volume":"35","author":"Abbott","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.heliyon.2024.e24559_bib8","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2019.05.58","article-title":"Immunotherapy and targeted therapy\u2014the new roadmap in cancer treatment","volume":"7","author":"Shahid","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.apnr.2013.08.004","article-title":"Effectiveness of nurse-delivered patient education interventions on quality of life in outpatients: a systematic review","volume":"26","author":"Strupeit","year":"2013","journal-title":"Appl. Nurs. Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib10","first-page":"1","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Communication and Signaling 2020"},{"key":"10.1016\/j.heliyon.2024.e24559_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-Targeted therapies \u2014 a role beyond breast cancer","volume":"17","author":"Oh","year":"2019","journal-title":"Nature Reviews Clinical Oncology 2019 17:1"},{"key":"10.1016\/j.heliyon.2024.e24559_bib12","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd.2018.21","article-title":"Kinase inhibitors: the road ahead","volume":"17","author":"Ferguson","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.heliyon.2024.e24559_bib13","first-page":"65","article-title":"Changes in cancer treatment: mabs, mibs, mids, nabs, and nibs","volume":"52","author":"Tariman","year":"2017","journal-title":"Nurs. Clin."},{"key":"10.1016\/j.heliyon.2024.e24559_bib14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejphar.2018.07.034","article-title":"Molecular targeted therapy: treating cancer with specificity","volume":"834","author":"Lee","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24559_bib15","first-page":"1","article-title":"Comprehensive review of targeted therapy for colorectal cancer","volume":"1","author":"Xie","year":"2020","journal-title":"Signal Transduction and Targeted Therapy 2020 5"},{"key":"10.1016\/j.heliyon.2024.e24559_bib16","first-page":"89","article-title":"Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy","volume":"17","author":"Zhang","year":"2007","journal-title":"Cell Research 2007 17"},{"key":"10.1016\/j.heliyon.2024.e24559_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.soncn.2014.05.002","article-title":"Science and mechanism of action of targeted therapies in cancer treatment","volume":"30","author":"Wujcik","year":"2014","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.heliyon.2024.e24559_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/1753466619831906","article-title":"Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases","volume":"13","author":"Tomasini","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.heliyon.2024.e24559_bib19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib20","first-page":"94","article-title":"Alectinib and brigatinib: new second-generation ALK inhibitors for the treatment of non\u2013small cell lung cancer","volume":"9","author":"Adv","year":"2018","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.heliyon.2024.e24559_bib21","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2147\/DDDT.S113500","article-title":"Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy","volume":"11","author":"Santarpia","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.heliyon.2024.e24559_bib22","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2016-0101","article-title":"Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib23","first-page":"1","article-title":"Emerging therapeutic agents for advanced non-small cell lung cancer","volume":"13","author":"Chen","year":"2020","journal-title":"Journal of Hematology & Oncology 2020 13:1"},{"key":"10.1016\/j.heliyon.2024.e24559_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19113491","article-title":"Receptor tyrosine kinase-targeted cancer therapy","volume":"19","author":"Yamaoka","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e24559_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/apjon.apjon_79_17","article-title":"Targeted therapy: attacking cancer with molecular and immunological targeted agents","volume":"5","author":"Wilkes","year":"2018","journal-title":"Asia Pac J Oncol Nurs"},{"key":"10.1016\/j.heliyon.2024.e24559_bib26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10637-013-9927-x","article-title":"The risk of hand-foot skin reaction to axitinib, a novel vegf inhibitor: a systematic review of literature and meta-analysis","volume":"31","author":"Fischer","year":"2013","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.heliyon.2024.e24559_bib27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.2017-0335","article-title":"Management of adverse events associated with cabozantinib therapy in renal cell carcinoma","volume":"23","author":"Schmidinger","year":"2018","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib28","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.2147\/OTT.S145295","article-title":"Practical management of adverse events associated with cabozantinib treatment in patients with renal-cell carcinoma","volume":"10","author":"Gerendash","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.heliyon.2024.e24559_bib29","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib30","first-page":"69","volume":"vol. 9","author":"Krajewska","year":"2015"},{"key":"10.1016\/j.heliyon.2024.e24559_bib31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.currproblcancer.2013.06.001","article-title":"US FDA approved oral kinase inhibitors for the treatment of malignancies","volume":"37","author":"Jeong","year":"2013","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib32","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0407","article-title":"Lenvatinib in management of solid tumors","volume":"25","author":"Hao","year":"2020","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib34","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.3748\/wjg.v17.i16.2113","article-title":"Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance","volume":"17","author":"Chen","year":"2011","journal-title":"World J. Gastroenterol. : WJG"},{"key":"10.1016\/j.heliyon.2024.e24559_bib35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in locally advanced or metastatic, radioactive iodine-refractory, differentiated thyroid cancer: a randomized, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e24559_bib36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2147\/DDDT.S82972","article-title":"Selective use of sorafenib in the treatment of thyroid cancer","volume":"10","author":"Pitoia","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.heliyon.2024.e24559_bib37","first-page":"348","article-title":"Ziv-aflibercept use in metastatic colorectal cancer","volume":"4","author":"Rodriguez","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"10.1016\/j.heliyon.2024.e24559_bib38","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/1756283X13502637","article-title":"Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations","volume":"6","author":"Tang","year":"2013","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.heliyon.2024.e24559_bib39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib40","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-12-0411","article-title":"Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and drug administration drug approval summary","volume":"18","author":"Thornton","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib41","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3389\/fphar.2019.00697","article-title":"Efficacy and safety of BcL-2 inhibitor venetoclax in hematological malignancy: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Li","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib42","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fonc.2019.01132","article-title":"Management of chronic myeloid leukemia in advanced phase","volume":"9","author":"Bonifacio","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib43","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome\u2013positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00063030-200822010-00007","article-title":"Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"22","author":"Keam","year":"2008","journal-title":"BioDrugs"},{"key":"10.1016\/j.heliyon.2024.e24559_bib45","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/oncolo\/oyab040","article-title":"FDA approval summary: revised indication and dosing regimen for ponatinib based on the results of the OPTIC trial","volume":"27","author":"Dianne Pulte","year":"2022","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-018-0685-2","article-title":"Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review","volume":"11","author":"Cortes","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1634\/theoncologist.2016-0456","article-title":"Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma","volume":"22","author":"Daud","year":"2017","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3390\/cancers12020482","article-title":"Current advances in the treatment of BRAF-mutant melanoma","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e24559_bib49","first-page":"17","volume":"vol. 22","author":"Schmitt","year":"2022"},{"key":"10.1016\/j.heliyon.2024.e24559_bib50","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e24559_bib51","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation\u2013positive hairy cell leukemia","author":"Kreitman","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24559_bib52","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.heliyon.2024.e24559_bib53","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1080\/10428194.2020.1783447","article-title":"Low-dose vemurafenib monotherapy in brafv600e-mutated erdheim-chester disease","volume":"61","author":"Ruan","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.heliyon.2024.e24559_bib54","first-page":"1066","volume":"vol. 62","author":"Ghia","year":"2021"},{"key":"10.1016\/j.heliyon.2024.e24559_bib55","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.3389\/fonc.2021.668162","article-title":"A selective bruton tyrosine kinase inhibitor for the treatment of B-cell malignancies","volume":"11","author":"Abbas","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib56","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.3389\/fphar.2020.625498","article-title":"The bruton's tyrosine kinase inhibitor ibrutinib impairs the vascular development of zebrafish larvae","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib57","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2217\/fon.14.51","article-title":"A first in class covalent inhibitor of bruton's tyrosine kinase","volume":"10","author":"Davids","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib58","doi-asserted-by":"crossref","first-page":"206","DOI":"10.5045\/br.2020.2020158","article-title":"Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world Data from a single-center study in Turkey","volume":"55","author":"G\u00f6\u00e7er","year":"2020","journal-title":"Blood Res"},{"key":"10.1016\/j.heliyon.2024.e24559_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-021-01463-2","article-title":"Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial","volume":"23","author":"Neven","year":"2021","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib60","first-page":"11","article-title":"Abemaciclib in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a phase 1b study","author":"Tolaney","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib61","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2019-0729","article-title":"Hormone receptor\u2013positive\/human epidermal growth receptor 2\u2013negative metastatic breast cancer in young women: emerging Data in the era of molecularly targeted agents","volume":"25","author":"Shah","year":"2020","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib62","volume":"vol. 53","author":"Rascon","year":"2018"},{"key":"10.1016\/j.heliyon.2024.e24559_bib63","first-page":"101","article-title":"Ribociclib in the treatment of hormone-receptor positive\/HER2-negative advanced and early breast cancer: overview of clinical Data and patients selection","volume":"14","author":"Parati","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib64","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s11523-017-0492-7","article-title":"Palbociclib: a review in HR-positive, HER2-negative, advanced or metastatic breast cancer","volume":"12","author":"Kim","year":"2017","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib65","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1177\/1078155220931926","article-title":"Afatinib for the treatment of EGFR mutation-positive NSCLC: a review of clinical findings","volume":"26","author":"Harvey","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.heliyon.2024.e24559_bib66","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","article-title":"Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib67","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib68","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","article-title":"Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment","volume":"8","author":"Zhang","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib69","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1158\/1078-0432.CCR-17-3628","article-title":"U.S. Food and drug administration approval: neratinib for the extended adjuvant treatment of early-stage HER2-positive breast cancer","volume":"24","author":"Singh","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib70","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1634\/theoncologist.2011-0461","article-title":"Lapatinib for advanced or metastatic breast cancer","volume":"17","author":"Opdam","year":"2012","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib71","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/annonc\/mdn759","article-title":"Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens","volume":"20","author":"Blackwell","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib72","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jjco\/hyz041","article-title":"Osimertinib for patients with EGFR T790M mutation-positive non\u2013small-cell lung cancer and a poor performance status","volume":"49","author":"Nakashima","year":"2019","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-07922-5","article-title":"Osimertinib in advanced EGFR-t790m mutation-positive non-small cell lung cancer patients treated within the special use medication program in Spain: OSIREX-Spanish lung cancer group","volume":"21","author":"Provencio","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10051109","article-title":"Real-world efficacy of midostaurin in aggressive systemic mastocytosis","volume":"10","author":"Szudy-Szczyrek","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib75","first-page":"1177","volume":"vol. 10","author":"Kayser","year":"2017"},{"key":"10.1016\/j.heliyon.2024.e24559_bib76","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2147\/OTT.S130910","article-title":"Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas","volume":"10","author":"Jain","year":"2017","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.heliyon.2024.e24559_bib77","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamaophthalmol.2020.1539","article-title":"Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial","volume":"138","author":"Ben Ishai","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.heliyon.2024.e24559_bib78","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100844","article-title":"Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results of a multicenter, open-label, phase 2 trial (VISMONEO study): neoadjuvant vismodegib in locally advanced basal cell carcinoma","volume":"35","author":"Bertrand","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.heliyon.2024.e24559_bib80","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127155","article-title":"Belinostat induces high overall response rate (ORR) in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL)","volume":"134","author":"Sawas","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24559_bib81","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib82","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1080\/10428194.2017.1361022","article-title":"Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy","volume":"59","author":"Duvic","year":"2018","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.heliyon.2024.e24559_bib83","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1586\/era.10.88","article-title":"Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors","volume":"10","author":"Grant","year":"2010","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.heliyon.2024.e24559_bib84","doi-asserted-by":"crossref","first-page":"12483","DOI":"10.1182\/blood-2022-159806","article-title":"Outcomes with panobinostat in heavily pretreated multiple myeloma patients","volume":"140","author":"Pan","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24559_bib85","first-page":"296","article-title":"Panobinostat (farydak): a novel option for the treatment of relapsed or relapsed and refractory multiple myeloma","volume":"41","author":"Moore","year":"2016","journal-title":"Pharmacy and Therapeutics"},{"key":"10.1016\/j.heliyon.2024.e24559_bib86","first-page":"377","article-title":"Update on the treatment of cutaneous T-cell lymphoma (CTCL): focus on vorinostat","volume":"1","author":"Duvic","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.heliyon.2024.e24559_bib87","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24559_bib88","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: a randomized phase 3 trial","volume":"141","author":"de Botton","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24559_bib89","first-page":"2271","volume":"vol. 356","author":"Hudes","year":"2007"},{"key":"10.1016\/j.heliyon.2024.e24559_bib90","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12032-009-9177-0","article-title":"Effect of temsirolimus versus interferon-\u03b1 on outcome of patients with advanced renal cell carcinoma of different tumor histologies","volume":"26","author":"Dutcher","year":"2009","journal-title":"Med. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib91","doi-asserted-by":"crossref","DOI":"10.21037\/atm-21-3840","article-title":"Combined everolimus and endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: a retrospective study","volume":"9","author":"Shen","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e24559_bib92","first-page":"1","article-title":"The kinase polypharmacology landscape of clinical PARP inhibitors","author":"Antolin","year":"2020","journal-title":"Scientific Reports 2020 10:1"},{"key":"10.1016\/j.heliyon.2024.e24559_bib93","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA approval summary: olaparib monotherapy or in combination with bevacizumab for the maintenance treatment of patients with advanced ovarian cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib94","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40265-017-0752-y","article-title":"First global approval","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e24559_bib95","first-page":"1010","volume":"vol. 54","author":"Kerliu","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e24559_bib96","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918778483","article-title":"Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy","volume":"10","author":"Dal Molin","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.heliyon.2024.e24559_bib97","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e24559_bib98","series-title":"Copanlisib for the Treatment of Adults with Relapsed Follicular Lymphoma","first-page":"813","author":"Magagnoli","year":"2020"},{"key":"10.1016\/j.heliyon.2024.e24559_bib99","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2147\/CMAR.S201024","article-title":"Copanlisib in the treatment of relapsed follicular lymphoma: utility and experience from the clinic","volume":"13","author":"Chauhan","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib100","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1001\/jamaoncol.2019.3994","article-title":"Idelalisib for treatment of relapsed follicular lymphoma and chronic lymphocytic leukemia: a comparison of treatment outcomes in clinical trial participants vs medicare beneficiaries","volume":"6","author":"Bird","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib101","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124013","article-title":"Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma treated with idelalisib in a community oncology setting","volume":"134","author":"Andorsky","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24559_bib102","first-page":"135","article-title":"Velcade (bortezomib) receives 2 new FDA indications: for retreatment of patients with multiple myeloma and for first-line treatment of patients with mantle-cell lymphoma","volume":"8","author":"Raedler","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.heliyon.2024.e24559_bib103","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40268-019-0269-9","article-title":"Bortezomib for the treatment of hematologic malignancies: 15 Years later","volume":"19","author":"Robak","year":"2019","journal-title":"Drugs R"},{"key":"10.1016\/j.heliyon.2024.e24559_bib104","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24559_bib105","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib106","first-page":"93","article-title":"Kyprolis (carfilzomib) received new indications as combination therapy for use in relapsed and\/or refractory multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.heliyon.2024.e24559_bib107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib111","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking of T Cells into tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib112","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","article-title":"Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer","volume":"37","author":"Hughes","year":"2016","journal-title":"Trends Immunol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib108","first-page":"193","article-title":"The immunobiology of cancer: from tumor escape to cancer immunoediting towards immunotherapy in gynecologic oncology","author":"Gasparri","year":"2017","journal-title":"Mol. Oncol.: Underlying Mechanisms and Translational Advancements"},{"key":"10.1016\/j.heliyon.2024.e24559_bib109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e24559_bib110","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2015.10.006","article-title":"Localized signals that regulate transendothelial migration","volume":"38","author":"Muller","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0393-z","article-title":"Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases","volume":"6","author":"Garcia","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J."},{"key":"10.1016\/j.heliyon.2024.e24559_bib118","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2147\/DDDT.S146286","article-title":"Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials","volume":"11","author":"Wang","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.heliyon.2024.e24559_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13887","article-title":"Systematic review of PD\u20101\/PD\u2010L1 inhibitors in oncology: from personalized medicine to public health","volume":"26","author":"Chang","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib115","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00091","article-title":"Potential immune-related adverse events associated with monotherapy and combination therapy of ipilimumab, nivolumab, and pembrolizumab for advanced melanoma: a systematic review and meta-analysis","volume":"10","author":"Almutairi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib119","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib120","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","article-title":"Association of immune-related adverse events with efficacy of atezolizumab in patients with non\u2013small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials","volume":"9","author":"Socinski","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib121","doi-asserted-by":"crossref","first-page":"S366","DOI":"10.1016\/j.jtho.2021.01.587","article-title":"Immune-related adverse events with durvalumab consolidation in a real-world cohort of patients with non\u2013small cell lung cancer (NSCLC)","volume":"16","author":"Montenegro","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib122","first-page":"E1","volume":"vol. 23","author":"Ugolini","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e24559_bib123","first-page":"12","article-title":"Chimeric antigen receptor-T cells: a pharmaceutical scope","author":"Hern\u00e1ndez-L\u00f3pez","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib124","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib125","first-page":"10","article-title":"Jun direct and indirect effects of IFN-\u03912b in malignancy treatment: not only an archer but also an arrow","author":"Xiong","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib126","first-page":"1","article-title":"Human interferon alpha-2b: a therapeutic protein for cancer treatment","author":"Ningrum","year":"2014","journal-title":"Scientifica (Cairo) 2014"},{"key":"10.1016\/j.heliyon.2024.e24559_bib127","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00262-016-1910-x","article-title":"Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma","volume":"65","author":"Alva","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.heliyon.2024.e24559_bib128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0333-y","article-title":"Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (MCRPC) using sipuleucel-T and a DNA vaccine","volume":"6","author":"Wargowski","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib130","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.heliyon.2024.e24559_bib131","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.3389\/fimmu.2021.737311","article-title":"The right partner in crime: unlocking the potential of the anti-EGFR antibody cetuximab via combination with natural killer cell chartering immunotherapeutic strategies","volume":"12","author":"Baysal","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib132","first-page":"215","article-title":"90Yttrium ibritumomab tiuxetan in the treatment of non-hodgkin\u2019s lymphoma: current status and future prospects","volume":"1","author":"Jacobs","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.heliyon.2024.e24559_bib133","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/2040620712458949","article-title":"Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use","volume":"3","author":"Warner","year":"2012","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.heliyon.2024.e24559_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10100342","article-title":"Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer","volume":"10","author":"Nami","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2024.e24559_bib135","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S1470-2045(21)00288-6","article-title":"Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials","volume":"22","author":"Bradley","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib136","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/21645515.2015.1129478","article-title":"Ipilimumab (Anti-Ctla-4 mab) in the treatment of metastatic melanoma: effectiveness and toxicity management","volume":"12","author":"Savoia","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e24559_bib137","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/gastro\/goaa026","article-title":"Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance","volume":"8","author":"Li","year":"2020","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1016\/j.heliyon.2024.e24559_bib138","doi-asserted-by":"crossref","first-page":"e2254","DOI":"10.1002\/onco.13971","article-title":"A long\u2010term extension study of bevacizumab in patients with solid tumors","volume":"26","author":"Oza","year":"2021","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib139","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00063030-200620040-00006","article-title":"Spotlight on rituximab in non-hodgkin lymphoma and chronic lymphocytic leukemia","volume":"20","author":"Cvetkovi\u0107","year":"2006","journal-title":"BioDrugs"},{"key":"10.1016\/j.heliyon.2024.e24559_bib140","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3324\/haematol.2015.124107","article-title":"Ofatumumab and its role as immunotherapy in chronic lymphocytic leukemia","volume":"100","author":"Sandhu","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2024.e24559_bib141","first-page":"113","article-title":"Radioimmunotherapy with tositumomab and iodine-131 tositumomab for non-hodgkin\u2019s lymphoma","volume":"1","author":"Andemariam","year":"2007","journal-title":"Biologics"},{"key":"10.1016\/j.heliyon.2024.e24559_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.013","article-title":"The future of immunotherapy in the treatment of cancer","volume":"35","author":"Kottschade","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.heliyon.2024.e24559_bib143","doi-asserted-by":"crossref","DOI":"10.1097\/01.coc.0000217877.78473.a4","article-title":"Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization","volume":"29","author":"Markovic","year":"2006","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib144","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s40425-019-0623-z","article-title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III\u2013iv melanoma","volume":"7","author":"Andtbacka","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib146","first-page":"603","volume":"vol. 14","author":"Karabajakian","year":"2017"},{"key":"10.1016\/j.heliyon.2024.e24559_bib147","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e24559_bib148","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib149","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e24559_bib150","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib151","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib152","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti\u2013PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24559_bib153","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.2980","article-title":"PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma","volume":"6","author":"Luke","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.heliyon.2024.e24559_bib154","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib155","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib156","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-Programmed-Death-Receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e24559_bib157","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib158","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib159","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib160","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib161","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum\u2010based doublet chemotherapy for first-line treatment of advanced non\u2013small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib162","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib163","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib164","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (eortc 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib165","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib166","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMc1807505","article-title":"Adjuvant pembrolizumab in resected stage III melanoma","volume":"379","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib167","series-title":"Combination with Nivolumab in Pts with Melanoma Who Progressed during Prior Anti\u2013PD-1\/pd-L1 Therapy (Mel Prior IO) in All-Comer and Biomarker-Enrich","first-page":"v611","article-title":"Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3)","author":"Ascierto","year":"2017"},{"key":"10.1016\/j.heliyon.2024.e24559_bib168","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4110\/in.2020.20.e20","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"key":"10.1016\/j.heliyon.2024.e24559_bib169","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib170","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ctrv.2014.06.012","article-title":"Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma","volume":"40","author":"McDermott","year":"2014","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.heliyon.2024.e24559_bib171","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib172","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1053\/j.seminoncol.2015.05.007","article-title":"Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy","volume":"42","author":"Wargo","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib173","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1158\/0008-5472.CAN-09-1456","article-title":"Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824","volume":"69","author":"Vo","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib174","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1073\/pnas.1011037108","article-title":"Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies","volume":"108","author":"Christiansen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.heliyon.2024.e24559_bib175","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-04-019711","article-title":"Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function","volume":"109","author":"Brogdon","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24559_bib176","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.4049\/jimmunol.173.6.4171","article-title":"Modulation of renal disease in MRL\/lpr mice by suberoylanilide hydroxamic acid","volume":"173","author":"Reilly","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib177","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.transproceed.2008.01.039","article-title":"Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+Regulatory T cells in rhesus macaques","volume":"40","author":"Johnson","year":"2008","journal-title":"Transplant. Proc."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e24559_bib178","first-page":"1299","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","author":"Tao","year":"2007","journal-title":"Nature Medicine 2007 13:11"},{"key":"10.1016\/j.heliyon.2024.e24559_bib179","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1158\/1078-0432.CCR-07-0014","article-title":"Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma","volume":"13","author":"Kato","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.coi.2013.02.011","article-title":"Combining cancer immunotherapy and targeted therapy","volume":"25","author":"Ribas","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib181","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cell.2009.12.040","article-title":"Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF","volume":"140","author":"Heidorn","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e24559_bib182","first-page":"427","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature 2010 464:7287"},{"key":"10.1016\/j.heliyon.2024.e24559_bib183","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","article-title":"PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells","volume":"23","author":"Halaban","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.heliyon.2024.e24559_bib184","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1105358","article-title":"RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors","volume":"366","author":"Su","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib185","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1056\/NEJMoa1208958","article-title":"Progression of RAS-mutant leukemia during RAF inhibitor treatment","volume":"367","author":"Callahan","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib186","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1200\/JCO.2011.36.7680","article-title":"RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors","volume":"30","author":"Oberholzer","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib187","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-11-2837","article-title":"BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy","volume":"72","author":"Koya","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib188","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.immuni.2011.04.006","article-title":"A central role for MTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity","volume":"34","author":"Li","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e24559_bib189","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.immuni.2009.10.010","article-title":"The MTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and eomesodermin","volume":"32","author":"Rao","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.heliyon.2024.e24559_bib190","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"MTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.heliyon.2024.e24559_bib191","doi-asserted-by":"crossref","unstructured":"Srivastava, R.K.; Utley, A.; Shrikant, P.A. Rapamycin. https:\/\/doi.org\/10.4161\/onci.20663 2012, 1, 1189\u20131190, doi:10.4161\/ONCI.20663.","DOI":"10.4161\/onci.20663"},{"key":"10.1016\/j.heliyon.2024.e24559_bib192","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib193","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/0008-5472.CAN-11-0307","article-title":"Immunotherapy with PI3K inhibitor and toll-like receptor agonist induces IFN-\u0393+IL-17+ polyfunctional T cells that mediate rejection of murine tumors","volume":"72","author":"Marshall","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib194","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1172\/JCI21102","article-title":"Novel mode of action of C-kit tyrosine kinase inhibitors leading to NK cell\u2013dependent antitumor effects","volume":"114","author":"Borg","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.heliyon.2024.e24559_bib195","first-page":"214","article-title":"A novel dendritic cell subset involved in tumor immunosurveillance","volume":"12","author":"Taieb","year":"2006","journal-title":"Nature Medicine 2006 12:2"},{"key":"10.1016\/j.heliyon.2024.e24559_bib196","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/nm.2438","article-title":"Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido","volume":"17","author":"Balachandran","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.heliyon.2024.e24559_bib197","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1182\/blood-2012-02-407163","article-title":"Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40","volume":"120","author":"Yang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e24559_bib198","doi-asserted-by":"crossref","first-page":"7730","DOI":"10.4049\/jimmunol.178.12.7730","article-title":"Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell","volume":"178","author":"Bae","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib199","doi-asserted-by":"crossref","first-page":"563","DOI":"10.4049\/jimmunol.1000222","article-title":"EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity","volume":"186","author":"Yun","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib200","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/bjc.2011.15","article-title":"Temsirolimus, an MTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines","volume":"104","author":"Wang","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib201","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.molimm.2010.05.003","article-title":"The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells","volume":"47","author":"Feng","year":"2010","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib202","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3324\/haematol.13783","article-title":"Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity","volume":"94","author":"Wang","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2024.e24559_bib203","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1189\/jlb.0711339","article-title":"Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression","volume":"91","author":"Rossi","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib204","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nri3129","article-title":"Experimental mouse tumour models: what can Be learnt about human cancer immunology?","volume":"12","author":"Dranoff","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.heliyon.2024.e24559_bib205","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1158\/0008-5472.CAN-05-2128","article-title":"Combination therapy with anti\u2013CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity","volume":"66","author":"Kocak","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2019.08.012","article-title":"Patient education issues and strategies associated with immunotherapy","volume":"35","author":"Lasa-Blandon","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.heliyon.2024.e24559_bib207","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.heliyon.2024.e24559_bib208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/jnr.0000000000000280","article-title":"Moving into action: the master key to patient education","volume":"27","author":"Fereidouni","year":"2019","journal-title":"J. Nurs. Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib209","article-title":"Chimeric antigen receptor T-cell therapy: a beacon of hope in the fight against cancer","volume":"10","author":"Tariq","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.heliyon.2024.e24559_bib210","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2147\/CMAR.S52543","article-title":"Real-world impact of education: treating patients with ipilimumab in a community practice setting","volume":"6","author":"Ledezma","year":"2013","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib211","first-page":"42","volume":"vol. 21","author":"McGettigan","year":"2017"},{"key":"10.1016\/j.heliyon.2024.e24559_bib212","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7748\/cnp.2017.e1391","article-title":"Approaches to patient education in managing adverse events of ipilimumab","volume":"16","author":"Fitzgerald","year":"2017","journal-title":"Cancer Nurs. Pract."},{"key":"10.1016\/j.heliyon.2024.e24559_bib213","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.soncn.2018.03.002","article-title":"Mobile applications, and wearable devices are expanding cancer care beyond walls","volume":"34","author":"Cannon","year":"2018","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.heliyon.2024.e24559_bib214","first-page":"407","article-title":"Health information on the internet: gold mine or minefield?","volume":"60","author":"Tonsaker","year":"2014","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.heliyon.2024.e24559_bib215","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.2196\/jmir.4333","article-title":"The impact of internet health information on patient compliance: a research model and an empirical study","volume":"17","author":"Laugesen","year":"2015","journal-title":"J. Med. Internet Res."},{"key":"10.1016\/j.heliyon.2024.e24559_bib216","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S2215-0366(17)30014-7","article-title":"Post-traumatic stress disorder and cancer","volume":"4","author":"Cordova","year":"2017","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.heliyon.2024.e24559_bib217","first-page":"76","volume":"22","author":"Apor","year":"2018","journal-title":"Prechemotherapy Education: Reducing Patient Anxiety Through Nurse-Led Teaching Sessions"},{"key":"10.1016\/j.heliyon.2024.e24559_bib218","series-title":"Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners","first-page":"105","article-title":"Springer nature, \u00a9; Switzerland, A.G. Nursing considerations for patients treated with targeted therapies","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e24559_bib219","first-page":"53","article-title":"Health literacy: exploring nursing challenges to providing support and understanding","volume":"22","author":"Wittenberg","year":"2018"},{"key":"10.1016\/j.heliyon.2024.e24559_bib220","doi-asserted-by":"crossref","first-page":"97","DOI":"10.17925\/EOH.2012.08.02.97","article-title":"Meeting educational needs and enhancing adherence of patients receiving oral cancer agents through use of the MASCC oral agent teaching Tool\u00a9","volume":"8","author":"Rittenberg","year":"2012","journal-title":"Eur Oncol Haematol"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024005905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024005905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:13:27Z","timestamp":1783930407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024005905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":220,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844024005905"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24559","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e24559"}}